Leadership
-
Heather Diehl/Getty Images via Getty Images
Pharma has friends in both parties this midterm season. Neither is offering a free pass.
As the industry donates and lobbies in both political directions, ongoing drug policy issues and a new head of PhRMA could complicate its traditional campaign playbook.
By Sy Mukherjee • Oct. 29, 2026 -
Permission granted by Courtesy of Immunic Therapeutics
MS has plenty of drugs. This Ocrevus veteran sees what’s missing.
After helping launch a blockbuster Roche and Genentech therapy, Erik Lundgren is betting Immunic's experimental drug can address persistent gaps in MS care, with pivotal trial results approaching.
By Alexandra Pecci • Oct. 26, 2026 -
Explore the Trendline➔
Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
Permission granted by Merck & Co.
ProfileA day in the life of a Merck R&D chief
Dr. Eliav Barr pulls back the curtain on what it's like to manage Merck’s fast-growing pipeline.
By Meagan Parrish • Oct. 9, 2026 -
Getty Images
Top pharma industry conferences in 2027
Where pharma and biotech leaders will converge to network, share ideas and potentially strike deals.
By Meagan Parrish • Oct. 6, 2026 -
Permission granted by Bavarian Nordic
What Bavarian Nordic’s next CEO is up against
The Danish biotech sharpened its global vaccine ambitions by tapping Tarja Stenvall, a Big Pharma vet, to take the helm.
By Alexandra Pecci • Sept. 28, 2026 -
Permission granted by Cocrystal Pharma
Q&A // First 90 DaysCocrystal Pharma’s new CEO hopes to crack the norovirus code
James Sapirstein is bringing his Big Pharma chops to the clinical-stage company’s efforts to finally deliver an effective treatment for the vexing stomach bug.
By Alexandra Pecci • Sept. 15, 2026 -
Alamy
Merck builds around Keytruda; prediction markets raise new risks
Merck pursues new cancer combinations, prediction markets put pharma’s confidential information in focus and personalized cancer vaccines confront manufacturing hurdles.
By PharmaVoice Staff • Sept. 11, 2026 -
Permission granted by Takeda
Andy Plump, architect of Takeda’s R&D overhaul, to retire next year
Plump joined Takeda during a turbulent period, pushed the company to work more closely with young biotechs and will leave it with what CEO Julie Kim called a “lasting foundation.”
By Kristin Jensen • Sept. 10, 2026 -
Sarah Silbiger via Getty Images
FDA gains ‘continuity’ as Mikhail, Davis named permanent CBER, CDER leaders
After almost two years of turnover in the FDA’s top ranks, the new appointments should help ease concerns about more turmoil ahead, one analyst said.
By Kristin Jensen • Sept. 9, 2026 -
Permission granted by Argenx
Q&A // First 90 DaysA single drug made Argenx one of the most valuable biotechs in Europe. Its new CEO is ready for the next act.
Under its new chief, Karen Massey, Argenx is positioning its blockbuster Vyvgart to become the Keytruda of the autoimmune disease space.
By Meagan Parrish • Aug. 28, 2026 -
Permission granted by GSK
Pharma’s new CEOs to watch
New leaders at GSK, Novo Nordisk and Sanofi are taking the reins at pivotal moments for three of pharma’s largest companies.
By Kelly Bilodeau • Aug. 27, 2026 -
Getty Images
Q&ALegend’s interim CEO sees a shorter path to the next era of CAR-T
Alan Bash explains how Carvykti informed the company’s strategy and what its in vivo platform still needs to prove.
By Sy Mukherjee • Aug. 25, 2026 -
Getty Images
OpinionThe scientific research pharma leaders keep sharing — and why
Six industry leaders share the scientific papers they keep circulating, spanning transplants, MASH, cancer, real-world evidence and trial design.
By Kelly Bilodeau • Aug. 20, 2026 -
Sarah Silbiger via Getty Images
Trump nominates policy aide Overton to lead FDA
Heidi Overton, a medical doctor and veteran of the America First think tank, currently serves as deputy director of the White House Domestic Policy Council.
By Kristin Jensen • Updated Aug. 19, 2026 -
Permission granted by Courtesy of Helus Pharma
Q&A // First 90 DaysHow Helus’ new CEO plans to scale its psychedelic drug pipeline
Can Michael Halstead replicate the controlled growth he pulled off at Intra-Cellular Therapies in mental health’s psychedelic era?
By Kelly Bilodeau • Aug. 18, 2026 -
Sean Gallup / Staff via Getty Images via Getty Images
BioNTech’s oncology pivot comes with a new CEO
Guido Oelkers will inherit a deep cancer pipeline, declining vaccine sales and $19 billion to fund the transition.
By Kelly Bilodeau • Aug. 14, 2026 -
Permission granted by Image courtesy of Formation Bio
Profile // First 90 DaysFormation Bio taps Biogen, Pfizer alum to tackle R&D’s ‘boring middle’
Dr. Michael Ehlers bets AI can ease the clinical-development bottleneck — but scaling Formation Bio’s pipeline will also require human judgment.
By Alexandra Pecci • Aug. 12, 2026 -
Sponsored by Courier Health
Specialty pharma has an infrastructure problem, and IT can’t solve it alone
Technology to enable the specialty patient journey is becoming IT's problem, but the fix isn't becoming the expert.
By Danny Sigurdson, Founder and CEO, Courier Health • Aug. 3, 2026 -
Getty Images
Opinion // First 90 DaysWhat pharma leaders wish they knew on day 1
PharmaVoice checked in with four life sciences executives after they landed a new role. Now they’re looking back on what they learned.
By Alexandra Pecci • July 9, 2026 -
Permission granted by Nuvation Bio
Doctor-turned-dealmaker reveals his M&A playbook
Dr. David Hung is pulling multiple financial levers to put Nuvation Bio on strong footing as it advances its oncology drugs.
By Kelly Bilodeau • July 1, 2026 -
Getty Images
OpinionBIO 2026: Where pharma leaders say AI hasn’t delivered
AI hasn’t always been what it was cracked up to be in pharma. Here’s where execs say the technology hasn’t lived up to the hype.
By Meagan Parrish • June 26, 2026 -
Getty Images
Recent pharma exec shake-ups signal strategic shifts
Whether from layoffs or exits, Novo Nordisk, Genentech and Allogene saw changes to their executive teams over the past few months.
By Kelly Bilodeau • June 24, 2026 -
Scott Olson via Getty Images
Pfizer CFO departs for consumer goods sector
Dave Denton joined Pfizer in 2022 from Lowe’s Companies and is leaving for an unspecified “professional opportunity” in consumer goods, the company said.
By Maura Webber Sadovi • Updated June 18, 2026 -
Getty Images
As M&A rebounds, here’s how pharmas can prepare to seal a deal
Drugmakers that aren’t ready when financial opportunity knocks could get caught flat-footed in a competitive market.
By Kelly Bilodeau • June 18, 2026 -
Getty Images
The biotech market is rebounding. So where are the executive jobs?
The industry is showing favorable economic signs, but biotech companies are still taking a measured approach to hiring leaders.
By Kelly Bilodeau • June 15, 2026
